{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"36","value":"22"},{"groupId":"OG001","lowerLimit":"18","upperLimit":"40","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Chronic graft vs host disease is defined in APPENDIX III of study protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tacro-MTX/Sirolimus GVHD Prophylaxis","id":"OG000","title":"Experimental"},{"description":"Tacro-MTX GVHD Prophylaxis","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"2 ineligible patients on experimental arm excluded from analysis. Definition of Chronic GVHD: APPENDIX III: DEFINING CHRONIC GRAFT VS. HOST DISEASE (FROM BMT CTN MOP SEPT. 2005) on page 97 protocol.","reportingStatus":"POSTED","timeFrame":"At 2 years","title":"Estimated Rate of Overall Chronic Graft VS Host Disease","type":"SECONDARY","unitOfMeasure":"percentage of participants"}